نتائج البحث - "Mennitto A."

1

دورية أكاديمية

A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluation of ARv7 in mCRPC patients with measurable metastases including visceral disease (Excalibur study).

المؤلفون: Sepe, Pierangela, Procopio, Giuseppe, Pircher, Chiara Carlotta, Basso, Umberto, Caffo, Orazio, Cappelletti, Vera, Claps, Melanie, De Giorgi, Ugo, Fratino, Lucia, Guadalupi, Valentina, Miodini, Patrizia, De Marco, Cinzia, Perrucci, Bruno, Mennitto, Alessia, Santini, Daniele, Spina, Francesco, Stellato, Marco, de Braud, Filippo, Verzoni, Elena

المصدر: Therapeutic Advances in Medical Oncology; 1/22/2024, p1-11, 11p

النص الكامل

2

دورية أكاديمية

Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?

المؤلفون: Roviello G., Buti S., Cattrini C., Mennitto A., Messina C., Airoldi C., Vannini G., Bersanelli M.

المساهمون: Roviello, G., Buti, S., Cattrini, C., Mennitto, A., Messina, C., Airoldi, C., Vannini, G., Bersanelli, M.

مصطلحات موضوعية: angiogenesi, endocrine toxicity, hypothyroidism, immune checkpoint inhibitor, immunotherapy, sunitinib, tyrosine kinase inhibitors

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000689544500001; volume:13; firstpage:17562872211029784; journal:THERAPEUTIC ADVANCES IN UROLOGY; http://hdl.handle.net/11381/2913730Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85109394470

الإتاحة: https://doi.org/10.1177/17562872211029784Test
http://hdl.handle.net/11381/2913730Test

View record in BASE

3

دورية أكاديمية

Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis

المؤلفون: Cattrini C., Messina C., Airoldi C., Buti S., Roviello G., Mennitto A., Caffo O., Gennari A., Bersanelli M.

المساهمون: Cattrini, C., Messina, C., Airoldi, C., Buti, S., Roviello, G., Mennitto, A., Caffo, O., Gennari, A., Bersanelli, M.

مصطلحات موضوعية: first-line, immune checkpoint inhibitor, meta-analysi, renal cell carcinoma, tyrosine kinase inhibitors

العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000713280500001; volume:13; firstpage:17562872211053189; journal:THERAPEUTIC ADVANCES IN UROLOGY; http://hdl.handle.net/11381/2913751Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85118432377

الإتاحة: https://doi.org/10.1177/17562872211053189Test
http://hdl.handle.net/11381/2913751Test

View record in BASE

4

دورية أكاديمية

The role of mean corpuscular volume and red cell distribution width in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: the MARECAP retrospective study.

المصدر: Therapeutic Advances in Urology; Jan-Dec2023, Vol. 15, p1-24, 24p

النص الكامل

5

دورية أكاديمية

Everolimus treatment for neuroendocrine tumors: Latest results and clinical potential

المؤلفون: Pusceddu, Sara, Verzoni, Elena, Prinzi, Natialie, Mennitto, Alessia, Femia, Daniela, Grassi, Paolo, Concas, Laura, Vernieri, Claudio, Lo Russo, Giuseppe, Procopio, Giuseppe

المساهمون: Pusceddu, Sara, Verzoni, Elena, Prinzi, Natialie, Mennitto, Alessia, Femia, Daniela, Grassi, Paolo, Concas, Laura, Vernieri, Claudio, Lo Russo, Giuseppe, Procopio, Giuseppe

مصطلحات موضوعية: everolimu, neuroendocrine tumor, RADIANT trial, Oncology

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/28344663; info:eu-repo/semantics/altIdentifier/wos/WOS:000395412100004; volume:9; issue:3; firstpage:183; lastpage:188; numberofpages:6; journal:THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY; https://hdl.handle.net/11573/1018484Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85014519320; http://tam.sagepub.com/content/by/yearTest

الإتاحة: https://doi.org/10.1177/1758834016683905Test
https://hdl.handle.net/11573/1018484Test
http://tam.sagepub.com/content/by/yearTest

View record in BASE